These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28943305)

  • 21. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromodomain inhibitors: what does the future hold?
    Bhattacharya S; Piya S; Borthakur G
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.
    Bechter O; Schöffski P
    Pharmacol Ther; 2020 Apr; 208():107479. PubMed ID: 31931101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel approaches to targeting BRD4.
    Kharenko OA; Hansen HC
    Drug Discov Today Technol; 2017 Jun; 24():19-24. PubMed ID: 29233295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of BET proteins in castration-resistant prostate cancer.
    Fernandez-Salas E; Wang S; Chinnaiyan AM
    Drug Discov Today Technol; 2016 Mar; 19():29-38. PubMed ID: 27769354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
    Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
    Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
    [No Abstract]   [Full Text] [Related]  

  • 30. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
    Jiménez I; Baruchel A; Doz F; Schulte J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phospho-BRD4: transcription plasticity and drug targeting.
    Chiang CM
    Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
    Sasaki K; Yoshida M
    Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
    Shi J; Vakoc CR
    Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
    Zhao Y; Yang CY; Wang S
    J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET Proteins as Targets for Anticancer Treatment.
    Stathis A; Bertoni F
    Cancer Discov; 2018 Jan; 8(1):24-36. PubMed ID: 29263030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
    Dutra LA; Heidenreich D; Silva GDBD; Man Chin C; Knapp S; Santos JLD
    Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.